The New York Times – Business:
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
The New York Times – Business:
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
The New York Times – Business:
The deal is a watershed for Hollywood, which has been trying to sort through the possible harms and upsides of generative artificial intelligence.
The New York Times – Business:
The Trump administration is threatening the Fed’s autonomy, which the central bank regained with the Treasury-Fed accord in 1951.
The New York Times – Business:
Shares in the technology company are down as investors grow anxious that its bet on artificial intelligence, and OpenAI in particular, may not pay off.
The New York Times – Business:
President Trump wants substantially lower borrowing costs, but officials at the central bank appear ready to resist delivering further cuts if the economic backdrop does not warrant it.
The New York Times – Business:
The president continues to brush off an issue that he said he would solve in his first months in office. Some Democrats say he is making the same mistake as his predecessor.
The New York Times – Business:
You may be surprised by the little-known and sometimes nonsensical rules lurking in the fine print. Here are a few that tripped up readers in 2025.
The New York Times – Business:
It’s hard to make a movie studio tour exciting when movies aren’t made there anymore. “A vibe of tiredness, like the end of something,” one guest said.
The New York Times – Business:
Desperate to catch up with Chinese automakers, Ford is redesigning its fleet with a Silicon Valley-style team. Is it too late?
The New York Times – Business:
At this year’s DealBook Summit, there was an understanding that in the Trump era, business runs through the White house like never before.